Peptide Intranasal Delivery Formulation Development

Nearly 40% of all new peptide drugs in development face a major problem: they break down before reaching their target in the body. Peptide intranasal delivery is one of the most promising ways researchers are solving this challenge.

The nose offers a direct route to the bloodstream and even the brain. This makes intranasal delivery a powerful option for peptides that would otherwise be destroyed by the digestive system.

What Is Peptide Intranasal Delivery?

Peptide intranasal delivery means giving a peptide drug through the nose. A patient uses a nasal spray or drop, and the peptide absorbs through the thin tissue lining the nasal cavity.

This tissue, called the nasal mucosa, has a rich blood supply and allows many molecules to pass directly into the bloodstream. For some peptides, the nasal route is faster and more efficient than injections.

Why the Nasal Route Matters for Peptide Drugs

Peptides are delicate molecules. When taken by mouth, stomach acid and digestive enzymes break them apart before they can do their job.

The nasal route skips the digestive system entirely. This means more of the drug reaches the bloodstream intact, which is called better bioavailability.

The nose also offers a special pathway to the brain. The olfactory nerve runs from the nasal cavity directly to the brain, and some peptides can travel along this path to treat brain conditions.

According to a 2024 review in the journal Drug Delivery, intranasal peptide delivery can achieve brain drug concentrations up to 5 times higher than intravenous injection for certain neuropeptides. This makes it a strong candidate approach for Alzheimer's and Parkinson's research.

The human nasal cavity has a surface area of about 150 square centimeters lined with highly vascularized tissue, yet most nasal peptide formulations only reach 10 to 20 percent of that absorptive area without optimized device design.

Key Benefits of Intranasal Peptide Formulation

Using the nasal route for peptide drugs offers many advantages for both patients and drug developers. Here are the most important ones.

Patients do not need needles. This makes treatment easier to accept, especially for long-term therapies. Better patient comfort leads to better treatment outcomes.

Nasal delivery also works quickly. Many peptides absorb within 15 to 30 minutes through the nasal mucosa, which is important for conditions that need fast relief.

Development costs can also be lower. Nasal formulations are often simpler to manufacture than injectable biologics, and they do not require sterile injection facilities.

Challenges in Nasal Peptide Formulation Development

Developing a good nasal peptide formulation is not simple. Several problems must be solved before a product can reach patients.

The nose clears foreign substances quickly, a process called mucociliary clearance. This can remove a drug before it fully absorbs, so formulators must design products that stick to the nasal tissue long enough to work.

Peptides also face enzyme activity in the nasal cavity. Enzymes called proteases can break down peptides even in the nose, so protective strategies are needed.

Challenge	Why It Matters	Common Solution
Mucociliary clearance	Removes drug too fast	Mucoadhesive polymers
Protease activity	Breaks down peptides	Enzyme inhibitors
Low membrane permeability	Limits absorption	Permeation enhancers
Peptide instability	Drug degrades in storage	Lyophilization
Nasal irritation	Poor patient acceptance	pH and tonicity control

Formulation Strategies for Nasal Peptide Drugs

Formulators use several tools to make nasal peptide drugs work better. Choosing the right strategy depends on the peptide's size, charge, and target.

Mucoadhesive agents like chitosan or carbopol make the drug stick to the nasal lining longer. This gives more time for absorption and reduces waste.

Permeation enhancers help larger peptides cross the nasal membrane. These agents temporarily open the tight junctions between cells, allowing more drug to pass through.

Nanoparticle encapsulation is another powerful tool. Enclosing a peptide in a lipid nanoparticle or polymer microsphere protects it from enzymes and helps it absorb more easily.

Cyclodextrins can also improve nasal peptide absorption. These ring-shaped molecules form complexes with peptides, improving their solubility and protecting them from degradation.

When evaluating intranasal peptide formulation partners, prioritize teams with in vivo nasal deposition data and mucoadhesive polymer expertise, because absorption enhancers alone won't solve retention problems caused by mucociliary clearance.

Key Formulation Components

A well-designed nasal peptide formulation contains several important ingredients beyond the active peptide.

Buffering agents keep the pH near the normal nasal range of 5.5 to 6.5. This protects both the peptide and the nasal tissue.

Preservatives prevent microbial growth in the product, especially important for multi-dose nasal sprays. Formulators must choose preservatives carefully because some irritate the nasal mucosa.

Tonicity agents match the salt concentration of nasal fluid. This prevents irritation and helps the product feel comfortable to use.

Nose-to-Brain Peptide Delivery

One of the most compelling uses of intranasal peptide delivery is treating brain diseases. The blood-brain barrier blocks most drugs from entering the brain through the bloodstream.

But the olfactory and trigeminal nerves provide a back door. Peptides applied to the upper part of the nasal cavity can travel along these nerves to reach the brain directly.

This nose-to-brain pathway is being studied for Alzheimer's disease, Parkinson's disease, depression, and stroke. Insulin nasal spray has shown promising results in memory and cognition research.

Dr. William Frey, a pioneer in intranasal drug delivery, noted: "The nose provides a direct highway to the brain that completely bypasses the blood-brain barrier. This could transform how we treat neurological diseases." His early work in the 1990s laid the foundation for modern nose-to-brain peptide research.

Regulatory Considerations for Nasal Peptide Products

Getting a nasal peptide drug approved requires careful attention to regulatory standards. The FDA and EMA have specific guidance for nasal spray and nasal solution products.

Manufacturers must prove the product delivers a consistent dose every time. This involves testing with nasal spray pumps and measuring droplet size, spray pattern, and plume geometry.

Learn more about peptide regulatory pathways on our regulatory compliance pages to understand what documentation is needed at each stage.

For full FDA guidance on nasal drug products, the FDA Nasal Spray and Inhalation Solution Draft Guidance is an essential reference.

Manufacturing and Scale-Up

Moving from a lab prototype to a commercial nasal peptide product requires solving new manufacturing challenges.

Nasal spray pumps must deliver exact doses every time. Pump selection and filling equipment must be validated carefully.

Peptides are sensitive to heat, light, and oxidation. Manufacturing environments must be controlled to protect product quality during production and packaging.

Cold chain requirements must also be planned early. Some nasal peptide products need refrigeration throughout distribution, which adds cost and complexity.

Current Market and Outlook

The global intranasal drug delivery market was valued at over 47 billion dollars in 2024 and is growing. Peptides are becoming a larger part of this market every year.

Several intranasal peptide products are already approved, including desmopressin for diabetes insipidus and calcitonin for osteoporosis. Many more are in clinical trials.

Nose-to-brain peptide therapies are an active area of development. As the science matures and formulation tools improve, more patients stand to benefit from this non-invasive delivery method.

Explore our peptide formulation development resources to learn about the full range of options available to drug developers.

FAQs

What is peptide intranasal delivery?

Peptide intranasal delivery is a method of giving peptide drugs through the nose using a nasal spray or drops. The peptide absorbs through the nasal mucosa directly into the bloodstream, avoiding the digestive system.

Why is intranasal delivery good for peptides?

The nasal route protects peptides from being broken down in the stomach and intestines. It also allows faster absorption and, for some peptides, direct delivery to the brain through the olfactory nerve.

What are the main challenges of nasal peptide formulations?

The main challenges include rapid mucociliary clearance, enzyme degradation of the peptide, low permeability for larger molecules, and ensuring patient comfort without irritation.

Which diseases are being treated with intranasal peptides?

Researchers are studying intranasal peptides for Alzheimer's disease, Parkinson's disease, diabetes, osteoporosis, depression, and hormonal disorders. Several products are already approved.

How long does it take to develop a nasal peptide formulation?

Basic formulation development typically takes 12 to 24 months. Full development through clinical trials can take many years, depending on the complexity of the molecule and the target condition.

What makes intranasal delivery different from injectable peptide drugs?

Intranasal delivery is needle-free, easier for patients to use at home, and can provide faster or more targeted delivery for brain conditions. However, it generally delivers smaller amounts of drug compared to injections.

Are intranasal peptide drugs safe?

When properly formulated and tested, intranasal peptide drugs are generally safe. Formulators must carefully control pH, preservatives, and excipients to avoid nasal irritation or tissue damage with long-term use.